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Abstract Metformin is in widespread clinical use for the
treatment of diabetes mellitus in patients. It has been shown
to inhibit mitochondrial bioenergetic functions by inhibiting
complex I of the electron transport chain. The expression of
mitochondrial-specific molecular stress protein Hsp60 is a
key consequence of mitochondrial impairment. Since this
protein has important immune-modulatory properties, we
have investigated the expression of Hsp60 in human THP-1
monocyte cells exposed to metformin. In this study, we
demonstrate significant up-regulation of Hsp60 at both
mRNA and protein levels when these cells were exposed to
metformin at therapeutic dosage levels. Interestingly, there
was also an increase in expression of CD14 mRNA in these
cells. This suggested a possible modulation of the differen-
tiation rates of the THP-1 cells during exposure to
metformin. As monocyte differentiation marks a critical
step in atherosclerosis, these observations suggest that long-
term exposure to metformin could have important implica-
tions for the diabetic patient.
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Introduction
Metformin (N-1,1-dimethylbiguanide) is an insulin sensi-
tizer which acts as an anti-hyperglycaemic agent used in the
treatment of newly diagnosed type 2 diabetes mellitus
patients. However, despite its widespread clinical use the
exact mode of action is still not known. A variety of
possible mechanisms have been suggested to explain its
ability to decrease fasting plasma glucose levels by 25–30%
including phosphorylation of insulin receptor and insulin
receptor substrate-2, inhibiting key enzymes in the gluco-
neogenic pathway, activation of pyruvate kinase, inhibition
of hepatic glucagon effects and reduction in hepatic uptake
of glucogenic substrates (lactate, alanine) (Goodarzi and
Bryer-Ash 2005). Interestingly, there is also accumulating
data in support of mitochondria being metformin’s primary
site of action. Metformin has been shown to affect complex
I of the mitochondrial respiratory chain (Brunmair et al.
2004; Guigas et al. 2004; Owen et al. 2000). Mitochondrial
complex I is also one of the main sites at which reactive
oxygen species can be generated (Brownlee 2001;
Nishikawa et al. 2000). Metformin has also been reported
to increase H2O2 production in rat liver mitochondria and
exacerbated Ca2+-induced mitochondrial permeability pore
opening in a concentration-dependent manner (Carvalho et
al. 2008). Moreover, metformin in cultured glioma cells has
been shown to cause mitochondrial depolarization and
oxidative stress-dependent apoptosis (Isakovic et al. 2007).
Collectively, these observations suggest that a key cellular
effect of metformin could be the general impairment of
mitochondrial bioenergetic functions.
An important cellular consequence of mitochondrial
bioenergetic impairment is the up-regulation of the expres-
sion levels of mitochondrial-specific molecular stress
protein Hsp60 (Martinus et al. 1996). This protein is
increasingly being implicated to play a key role as a
powerful immunogen and immunomodulator in experimen-
tal models of arthritis, diabetes (type 1) and atheroscelerosis
(Shamaei-Tousi et al. 2007).
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Since monocyte cells are able to elicit innate immune
responses and play important roles in the pathogenesis of
atherosclerosis, a human monocyte cell line (THP-1 cells)
was used in this study to see if metformin at therapeutic
levels was indeed able to modulate the expression of
mitochondrial Hsp60. And to see if any changes in the
levels of Hsp60 had functional consequences for these
monocytic cells.
Materials and methods
Cell culture
Human acute monocytic leukaemia cell line (THP-1) was
purchased from the American Tissue Culture Collection
(no. TIB-202). These cells were cultured in THP-1 media
containing RPMI Media 1640 (Gibco) supplemented with
10% foetal bovine serum (FBS), 1 mM pyruvate, and 1×
penicillin/streptomycin. Cells were grown at 37°C, 5% CO2
in a humidified incubator. All experiments were carried out
using near-confluent cells which had been passaged 2 days
prior to the experiments.
Differentiating THP-1 cells
Phorbol 12-myristate 13-acetate (PMA) (Sigma) was used
to stimulate differentiation of monocyte cells into macro-
phages. Using 24-well plates, near-confluent THP-1 cells
were cultured in metformin-containing media (0, 100 μM)
and treated with 50 nM PMA for 2–3 days or until cells
showed macrophage characteristics under the microscope.
LDH assay
Lactate dehydrogenase (LDH) is a cytosolic enzyme which
is released into the media by dead cells. The Promega
CytoTox96 NonRadioactive Cytotoxicity Assay kit was
used to determine LDH content according to the manufac-
turer’s instructions. The assay was ended by the addition of
stop solution and the resulting coloured mixture was read at
490 nm on a microplate reader (Bio-Rad). The data is
presented as a percentage and can be interpreted as the
percentage of dead cells present in the original culture,
assuming that each dead cell released an equal amount of
LDH content.
MTT assay
The conversion of the tetrazolium salt redox dye, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), into a formazan product was used as an assay for
mitochondrial dehydrogenase activity. After exposure of
THP-1 cells to various concentrations of metformin, the
MTT reduction was determined colorimetrically at 570 and
655 nm using the Sigma MTT-based In vitro Toxicology
Assay Kit according to the manufacturer’s protocol.
Protein extraction and Western blot analysis
The extraction of cellular protein, SDS-PAGE and Western
blot analysis was carried out as essentially described in
Martinus et al. (1996). Briefly, total protein was extracted
using TENT buffer (50 mM Tris, 250 mM NaCl, 5 mM
EDTA, 1% Triton X-100 and freshly supplemented 0.4 mM
phenylmethylsulfonyl fluoride). Protein concentration was
estimated using the BCA Protein Assay Kit (Pierce) and
15 μg total protein was separated by SDS-PAGE. Proteins
were then transferred to a nitrocellulose membrane (Bio-
Rad) and probed with Ponceau S staining to ensure that
there was equal loading of proteins across all lanes prior to
the Western blotting analysis. After blocking with 10%
skim milk, the membrane was incubated with polyclonal
rabbit anti-Hsp60 (Stressgen SPA805) followed by
peroxidase-conjugated goat anti-rabbit IgG (Sigma). The
membrane was incubated with SuperSignal West Pico
Chemiluminescent Substrate (Pierce) and the Hsp60 protein
band visualised through LAS-1000 Plus Gel Documenta-
tions System (Fujifilm). The intensity of the bands was
analysed using the Gel Quant software.
Hsp60 and CD14 mRNA expression
To quantify the Hsp60 and CD14 mRNA expression in the
THP-1 cells, total RNA was extracted using TRIzol
(Invitrogen) according to the manufacturer’s protocol.
RNA integrity was checked either by 260/280 nm ratio by
Nanodrop ND-1000 spectrophotometer (Nanodrop) or
discernable rRNA bands on an 1% agarose gel buffered in
TBE.
DNase I treatment and semi quantitative PCR
RNA samples were treated with amplification grade DNase
I (Roche) before cDNA synthesis to remove any contam-
inating genomic DNA. cDNA template was synthesised
using the Roche two-step RT-PCR kit following the
manufacturer’s protocol. PCR amplification was carried
out using FastStart Taq Polymerase (Roche). Each PCR
reaction contained 1 μL cDNA, 1× PCR buffer (MgCl2),
0.2 mM dNTP, 0.1 μM forward and reverse primers
(Invitrogen), 0.2 μL FastStart Taq Polymerase and the
volume was made up to 25 μL with PCR water. Each PCR
run included a negative control containing 1 μL PCR water
instead of cDNA. The thermocycling conditions for Hsp60
Cd14 and Gapdh (the house keeping gene) were as follows:
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Hsp60, denaturation at 95°C for 1 min, annealing at 55°C
for 1 min, extension at 72°C for 1 min; Cd14, denaturation
at 95°C for 1 min, annealing at 52°C for 30 s, extension at
72°C for 30 s; Gapdh, denaturation at 95°C for 1 min,
annealing at 60°C for 1 min, extension at 72°C for 1 min.
The primer sequences used for Hsp60 was forward: TTC
GAT GCATTC CAG CTT G and reverse: TTG GGC TTC
CTG TCA CAG TT, for Cd14 was forward: CTG CAA
CTT CTC CGA ACC TC and reverse: CCA GTA GCT
GAG CAG GAA CC, for Gapdh was forward: ACC ACA
GTC CAT GCC ATC AC and reverse: TCC ACC ACC
CTG TTG CTG TA.
The number of cycles that lied within the linear
amplification range was used to quantitate the gene of
interest by normalising to Gapdh expression levels. The
PCR products were run, along with a DNA ladder, on a 1%
agarose gel stained with EtBr and buffered in 1× TAE. The
intensity of the bands was analysed using the Gel Quant
software (DNR Bio-Imaging Systems).
Statistical analysis
All statistical analysis in this study was carried out using
Microsoft Excel. Data were averaged when appropriate and
standard error of the mean (S.E.M.) was calculated in
Excel. A two-tailed student’s t test was carried out to
determine the significance of the data. The accepted level
of significance was p<0.05, which was denoted as “*”,
whereas p<0.01 was denoted as “#” throughout this study.
Fig. 1 Growth rate of THP-1 cells in the presence of varying
concentration of metformin. Error bars show S.E.M. from three
independent experiments
Fig. 3 Hsp60 protein expression in response to metformin exposure.
The THP-1 cells were treated for 3 and 7 days. Bar graphs represent
mean±S.E.M. from two independent experiments
Fig. 4 Percentage of lysed cells in the presence of metformin. Bar
graph showing means±S. E.M. from three independent experi-
ments*p<0.05
Fig. 2 Hsp60 mRNA expression in response to metformin. The THP-
1 cells were treated for 3 and 7 days. Bar graphs represent mean±S.E.
M. from three independent experiments * p<0.05 and #p<0.01
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Results and discussion
Under the growth conditions used in this study, the THP-1
monocyte cells had a doubling time of 48 h. Cells exposed
to metformin at 100 and 250 μM showed a slightly reduced
growth rate compared with control cells and those exposed
to 500 μM and 1 mM had 74% and 48% of the control cell
numbers, respectively. At levels of 10 mM metformin was
cytotoxic to the cells and they were unable to multiply and
were no longer viable after 2 days (Fig. 1). At these high
metformin levels, we also observed a marked acidification
of the growth media (data not shown). This was possibly
due to a buildup of lactate, a consequence of these cells
relying on glycolysis to compensate for reduced ATP
production via oxidative phosphorylation (Martinus et al.
1993). The metformin toxicity profile seen in this study was
comparable to those reported using primary human hep-
atocytes and HepG2 cells (Dykens et al. 2008).
Since metformin has been documented to inhibit
complex I of the mitochondrial respiratory chain, we
investigated to see if THP-1 cells exposed to metformin at
therapeutically relevant levels of 100, 250 and 500 μM led
to modulation of the mitochondrial-specific stress protein
Hsp60. After 3 days of exposure to metformin at 100, 250
and 500 μM, there was no significant differences in the
expression of Hsp60 mRNA levels between treated and
control THP-1 cells. However, after 7 days of incubation
there was an increase in Hsp60 mRNA at all concentrations
of metformin compared with untreated control THP-1 cells
(Fig. 2). Hsp60 mRNA had a 7.27±0.40-, 6.67±0.82-, and
9.68±0.23-fold increase in the 100, 250 and 500 μM
groups, respectively (Fig. 2). The growth rate for THP-1
cells exposed to metformin for 7 days at the various
concentrations was similar to the initial growth rates shown
in Fig. 1. Metformin was not therefore having a cumulative
effect on these cultured cells during the longer incubation
period (data not shown).
In order see if this increase in expression of Hsp60
mRNA translated to an increase also at the protein level,
Western blot analysis was carried out on proteins extracted
from THP-1 cells exposed to various metformin concen-
trations over the 3- and 7-day exposure experiments. At
3 days, there was no significant change in expression of
Hsp60 protein levels at 100 and 250 μM metformin. There
was however a 1.62-fold increase in Hsp60 protein level at
500 μM metformin (Fig. 3). In contrast, after 7 days of
exposure to metformin at 250 and 500 μM, there was an
11- and 26-fold increase in Hsp60 protein levels respec-
tively (Fig. 3).
The release of lactate dehydrogenase into the growth
media (LDH assay) was used to determine the cytotoxicity
of metformin. The untreated control THP-1 cells had 45%
of lysed cells and were not significantly different to cells
exposed to 100 and 250 μM metformin which had 44% and
45% of lysed cells, respectively (Fig. 4). However,
exposure to 500 μM metformin resulted in a significantly
reduced (P<0.05) percentage of lysed cells compared with
the untreated control THP-1 cells (Fig. 4). The LDH data
suggest that the increase in expression of Hsp60 observed
at both mRNA and protein levels were not due to cellular
lysis and that the growth inhibitory effects of 500 μM
Fig. 5 Mitochondrial dehydrogenase activity. Bar graph showing
means±S.E.M. from three independent experiments #p<0.01
Fig. 6 Phase contrast microp-
graphs showing THP-1 mono-
cytes stained with blue formazan
deposits intracellular after
30-min incubation. a Ctrl con-
trol, b 500 μM metformin.
Maginification ×400
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metformin was not due to cell death but possibly due to
metformin having an inhibitory effect on mitochondrial
bionenergetic functions. Interestingly, metformin has been
documented to prevent cell death by modulation of the
mitochondrial permeability transition pore opening induced
by a glutathione-oxidising agent t-butyl hydroperoxide
(Guigas et al. 2004) and also due to high glucose-induced
cell death in a human dermal microvascular endothelial cell
line, HMEC-1 (Detaille et al. 2005). However, reports of
metformin treatment resulting in an increase in H2O2
production in rat liver mitochondria (Carvalho et al.
2008), a short-term trial involving 15 type 2 diabetes
mellitus patients treated with metformin showing an
elevation in oxidative stress, indicated by elevated mali-
dialdehyde levels (Škrha et al. 2007) and metformin
causing mitochondrial depolarization and oxidative stress-
dependent apoptosis in cultured glioma cells (Isakovic et al.
2007), suggest that the role of mitochondria in metformin-
induced cytotoxicity remains to be of defined.
The MTT assay indicated a significant (P<0.01) 41%
inhibition of mitochondrial dehydrogenase activity at
500 μM metformin compared to untreated control THP-1
cells (Fig. 5). In order to minimise the extramitochondrial
reduction of the formazan dye, the assay was stopped as
soon as the formazan crystals were observed under a light
microscope (Fig. 6). These results are comparable to earlier
observations which documented the inhibition of 53% of
respiration in human carcinoma-derived KB cells after
exposure to 10 mM metformin (Guigas et al. 2004).
In order to see if the up-regulation of Hsp60 in THP-1
cells as a consequence of exposure to metformin had any
functional significance to these monocyte cells, we inves-
tigated the effect of metformin on the differentiation of the
THP-1 cells. Differentiation of the THP-1 monocyte cells
was achieved by phorbol 12-myristate 13-acetate (PMA).
After 48 h of exposure to PMA, cells exhibited character-
istic morphology of macrophages such as adhesion and
spreading (Fig. 7). When cells were differentiated in the
presence of 100 μM metformin, they showed a significant
(p<0.05) 1.48-fold increase in the expression of CD14
mRNA compared to control cells (Fig. 8). CD14 is a
specific surface receptor known to be expressed on macro-
phages (Tuomisto et al. 2005). The expression of CD14 at
the protein level has yet to be established. We suggest the
possibility that monocyte cells exposed to metformin could
result in a modulation of the differentiation of these cells.
Interestingly, there was also a significant elevation in the
levels of Hsp 60 mRNA after differentiation (P<0.05;
Fig. 7 Phase contrast
micrographs showing THP-1
monocytes (a) and PMA-treated
THP-1 cells showing macro-
phage morphologies (b).
Magnification ×400
Fig. 8 Expression of CD14 and
Hsp60 mRNA in metformin
treated THP-1 derived macro-
phages. Bar graphs show means
±S.E.M. from three independent
experiments *p<0.05; #p<0.01
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Fig. 8). The precise reason for the up-regulation of Hsp60
mRNA after differentiation of the THP-1 cells is not yet
known. Interestingly, we have also observed a higher level
of Hsp60 mRNA in primary monocytes isolated from
T2DM patients being treated with metformin compared to
patients on no-medication and non-diabetic control subjects
(data not shown). High circulating levels of Hsp60 has been
documented in a number of studies in patients with diabetes
mellitus (Imatoh et al. 2009; Shamaei-Tousi et al. 2006).
The source of the serum Hsp60 is not yet known. It is
tempting to speculate that mitochondrially stressed mono-
cytes could be a potential source of serum Hsp60. We
suggest that the elevated Hsp60 at mRNA and protein
levels could be a reflection of the influx of newly
synthesised proteins due to the transition from monocyte
to macrophage phenotypes, an increased requirement for
cytoprotection due to oxidative damage associated with
macrophage respiratory bust, and/or a cellular stress
condition caused by metformin treatment. Interestingly,
the transcriptional activation of Hsp60, Hsp70 and HSp90
has been documented in peritoneal macrophages induced
by colony-stimulating factor (Teshima et al. 1996). The
transcription of these genes coincided with O2- production
by macrophages stimulated with PMA indicated that heat
shock proteins may play a protective role against harmful
oxidative damage associated with the respiratory burst
(Teshima et al. 1996).
In conclusion, we demonstrate for the first time that
THP-1 monocyte cells exposed to metformin at the
therapeutic range expressed higher levels of Hsp60 at both
mRNA and protein levels. Since monocyte activation and
recruitment and subsequent differentiation into macro-
phages are critical steps in the development of atheroscle-
rosis (Libby et al. 2002; Ludewig and Laman 2004), further
investigation of the role of metformin induced modulation
of Hsp60 and CD14 could have important implications for
type 2 diabetes mellitus patients being treated long-term
with metformin.
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